242 related articles for article (PubMed ID: 27530552)
1. Targeted nanoconjugate co-delivering siRNA and tyrosine kinase inhibitor to KRAS mutant NSCLC dissociates GAB1-SHP2 post oncogene knockdown.
Srikar R; Suresh D; Zambre A; Taylor K; Chapman S; Leevy M; Upendran A; Kannan R
Sci Rep; 2016 Aug; 6():30245. PubMed ID: 27530552
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab-siRNA Conjugate Linked Through Cationized Gelatin Knocks Down KRAS G12C Mutation in NSCLC Sensitizing the Cells Toward Gefitinib.
Sreedurgalakshmi K; Srikar R; Harikrishnan K; Srinivasan L; Rajkumari R
Technol Cancer Res Treat; 2021; 20():15330338211041453. PubMed ID: 34542333
[TBL] [Abstract][Full Text] [Related]
3. Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations.
Furcht CM; Muñoz Rojas AR; Nihalani D; Lazzara MJ
Oncogene; 2013 May; 32(18):2346-55, 2355.e1-10. PubMed ID: 22777356
[TBL] [Abstract][Full Text] [Related]
4. Interaction of scaffolding adaptor protein Gab1 with tyrosine phosphatase SHP2 negatively regulates IGF-I-dependent myogenic differentiation via the ERK1/2 signaling pathway.
Koyama T; Nakaoka Y; Fujio Y; Hirota H; Nishida K; Sugiyama S; Okamoto K; Yamauchi-Takihara K; Yoshimura M; Mochizuki S; Hori M; Hirano T; Mochizuki N
J Biol Chem; 2008 Aug; 283(35):24234-44. PubMed ID: 18577518
[TBL] [Abstract][Full Text] [Related]
5. Gab1 transduces PI3K-mediated erythropoietin signals to the Erk pathway and regulates erythropoietin-dependent proliferation and survival of erythroid cells.
Fukumoto T; Kubota Y; Kitanaka A; Yamaoka G; Ohara-Waki F; Imataki O; Ohnishi H; Ishida T; Tanaka T
Cell Signal; 2009 Dec; 21(12):1775-83. PubMed ID: 19665053
[TBL] [Abstract][Full Text] [Related]
6. EGFR-activated Src family kinases maintain GAB1-SHP2 complexes distal from EGFR.
Furcht CM; Buonato JM; Lazzara MJ
Sci Signal; 2015 May; 8(376):ra46. PubMed ID: 25969544
[TBL] [Abstract][Full Text] [Related]
7. Signal strength dictates phosphoinositide 3-kinase contribution to Ras/extracellular signal-regulated kinase 1 and 2 activation via differential Gab1/Shp2 recruitment: consequences for resistance to epidermal growth factor receptor inhibition.
Sampaio C; Dance M; Montagner A; Edouard T; Malet N; Perret B; Yart A; Salles JP; Raynal P
Mol Cell Biol; 2008 Jan; 28(2):587-600. PubMed ID: 18025104
[TBL] [Abstract][Full Text] [Related]
8. Dioscin overcome TKI resistance in EGFR-mutated lung adenocarcinoma cells via down-regulation of tyrosine phosphatase SHP2 expression.
Wang YC; Wu DW; Wu TC; Wang L; Chen CY; Lee H
Int J Biol Sci; 2018; 14(1):47-56. PubMed ID: 29483824
[TBL] [Abstract][Full Text] [Related]
9. Hexachlorophene, a selective SHP2 inhibitor, suppresses proliferation and metastasis of KRAS-mutant NSCLC cells by inhibiting RAS/MEK/ERK and PI3K/AKT signaling pathways.
Fu NJ; Xi RY; Shi XK; Li RZ; Zhang ZH; Li LY; Zhang GL; Wang F
Toxicol Appl Pharmacol; 2022 Apr; 441():115988. PubMed ID: 35307375
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with KRAS siRNA and EGFR inhibitor AZD8931 suppresses lung cancer cell growth in vitro.
Zarredar H; Pashapour S; Ansarin K; Khalili M; Baghban R; Farajnia S
J Cell Physiol; 2019 Feb; 234(2):1560-1566. PubMed ID: 30132854
[TBL] [Abstract][Full Text] [Related]
11. Protein Tyrosine Phosphatase Non-Receptor 11 (
Richards CE; Elamin YY; Carr A; Gately K; Rafee S; Cremona M; Hanrahan E; Smyth R; Ryan D; Morgan RK; Kennedy S; Hudson L; Fay J; O'Byrne K; Hennessy BT; Toomey S
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445722
[No Abstract] [Full Text] [Related]
12. Acquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants.
Fan YX; Wong L; Marino MP; Ou W; Shen Y; Wu WJ; Wong KK; Reiser J; Johnson GR
J Biol Chem; 2013 Jun; 288(23):16895-16904. PubMed ID: 23612964
[TBL] [Abstract][Full Text] [Related]
13. SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells.
Jiang L; Xu W; Chen Y; Zhang Y
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3231-3238. PubMed ID: 31373232
[TBL] [Abstract][Full Text] [Related]
14. Participation of both Gab1 and Gab2 in the activation of the ERK/MAPK pathway by epidermal growth factor.
Meng S; Chen Z; Munoz-Antonia T; Wu J
Biochem J; 2005 Oct; 391(Pt 1):143-51. PubMed ID: 15952937
[TBL] [Abstract][Full Text] [Related]
15. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
[TBL] [Abstract][Full Text] [Related]
16. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.
Jiang ZB; Huang J; Xie C; Li X; Liu L; He J; Pan H; Huang L; Fan XX; Yao XJ; Xie Y; Li N; Liu L; He JX; Leung EL
Oncol Rep; 2016 Jul; 36(1):365-75. PubMed ID: 27121230
[TBL] [Abstract][Full Text] [Related]
17. Gab1, SHP2, and protein kinase A are crucial for the activation of the endothelial NO synthase by fluid shear stress.
Dixit M; Loot AE; Mohamed A; Fisslthaler B; Boulanger CM; Ceacareanu B; Hassid A; Busse R; Fleming I
Circ Res; 2005 Dec; 97(12):1236-44. PubMed ID: 16284184
[TBL] [Abstract][Full Text] [Related]
18. Targeting the KRAS, p38α, and NF-κB in lung adenocarcinoma cancer cells: The effect of combining RNA interferences with a chemical inhibitor.
Zarredar H; Pashapour S; Farajnia S; Ansarin K; Baradaran B; Ahmadzadeh V; Safari F
J Cell Biochem; 2019 Jun; 120(6):10670-10677. PubMed ID: 30656741
[TBL] [Abstract][Full Text] [Related]
19. PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.
Chen X; Zou F; Hu Z; Du G; Yu P; Wang W; Wang H; Ye L; Tian J
Toxicol Appl Pharmacol; 2020 Jul; 398():115019. PubMed ID: 32335126
[TBL] [Abstract][Full Text] [Related]
20. Silencing AXL by covalent siRNA-gelatin-antibody nanoconjugate inactivates mTOR/EMT pathway and stimulates p53 for TKI sensitization in NSCLC.
Suresh D; Zambre A; Mukherjee S; Ghoshdastidar S; Jiang Y; Joshi T; Upendran A; Kannan R
Nanomedicine; 2019 Aug; 20():102007. PubMed ID: 31085346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
